The company is headquartered in Zhoupu Medical Park in Shanghai. It was founded in March 2004 by entrepreneur Mr. Du Jinhao and Dr. Guo Jianhui, who has the honor of being a lifelong scientist from the US National Institutes of Health (NIH). Iris is an innovative pharmaceutical company integrating R&D, production and marketing. It is committed to developing and producing innovative drugs with independent intellectual property rights, safe, effective and beneficial to the public, with the development concept of Chinese innovation and caring for global patients, guided by the unmet clinical needs of the global pharmaceutical market, focusing on the field of cancer treatment, with the goal of developing first-in-class drugs (first-in-class) and best-in-class drugs (best-in-class). The company is an innovative drug enterprise focusing on the field of tumor treatment, and has now built an advantageous R&D pipeline in the field of small molecule targeted drugs for non-small cell lung cancer (NSCLC). The main products are vometinib mesylate tablets and platinib capsules. Corporate honors: “Pharmaceutical Innovation Achievement Award of the Year”, “2020 Ji World Cup Top Ten Pharmaceutical Innovation Emerging Companies of the Year”, “Top 10 Best Biomedical Listed Companies”, and 2021 China Pharmaceutical Emerging Innovation Force Enterprise. The company won honorary titles such as “2020 World Cup Top Ten Emerging Pharmaceutical Innovation Companies” hosted by the Securities Times, “Top 10 Best Biomedical Listed Companies” in the 2020 China Healthcare Industry Investment and Financing Honor List, and 2021 China Pharmaceutical Emerging Innovation Force Enterprise.
No Data